Biosimilar facility

Setting a New Standard in Biosimilars

Alvogen’s sister company, Alvotech, is a fully integrated specialty biopharmaceutical company focused exclusively on development and manufacturing of high-quality biosimilar medicines. They are specialists in biopharmaceutical product creation, all along the value chain from cell line development to commercial manufacturing.

Lab woman and man

Fully integrated development

Alvotech is focused on developing and bringing to market highest quality biosimilars. The current pipeline consists of biosimilar monoclonal antibodies aimed at treating cancer, autoimmune, inflammatory and other diseases.



These products are developed in our four Research & Development centers located across Europe.



High-quality products will be manufactured in our state-of-the-art facility located in Reykjavik Iceland.



Partnership through Alvogen and key global players will be used to bring biosimilars to patients around the world.

Seringe line

In-house research and development

Alvotech is uniquely positioned with a fully integrated R&D and manufacturing engine, driven by best-in-class in-house research and development. Its state-of-the-art manufacturing facility fill finish capacity, situated in a patent-friendly location in Reykjavik, Iceland. Mark Levick leads the Alvotech team with over 400 colleagues who are passionate about transforming patients’ lives and bringing high-quality biopharmaceuticals to market.

Pioneering Biogenerics
We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.